Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
PVd Versus Vd in NDMM Patients With RI
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 79
- Registration Number
- NCT05432414
- Locations
- 🇨🇳
Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Xia Zhongjun
- Target Recruit Count
- 42
- Registration Number
- NCT05422027
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China,, Guangzhou, Guangdong, China
🇨🇳Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 49
- Registration Number
- NCT05392946
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Bortezomib for Treating Glomerular Diseases
- Conditions
- MNBortezomibGlomerulonephritisMPGNFSGSIgA Nephropathy
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05383547
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
- Conditions
- Stem Cell Transplantation
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05293509
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
- Conditions
- Graft-versus-host Disease
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 74
- Registration Number
- NCT05289167
- Locations
- 🇺🇸
Northwell Health, New Hyde Park, New York, United States
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
- Conditions
- Multiple Myeloma
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Canadian Myeloma Research Group
- Target Recruit Count
- 75
- Registration Number
- NCT05272826
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦London Health Sciences Centre, London, Ontario, Canada
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 750
- Registration Number
- NCT05257083
- Locations
- 🇺🇸
University of Arkansas, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸UC San Diego Health Moores Cancer Center, San Diego, California, United States
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
- Conditions
- Amyloidosis
- Interventions
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 150
- Registration Number
- NCT05250973
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Smilow Cancer Hospital/Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
- Conditions
- Solitary Plasmacytoma
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 220
- Registration Number
- NCT05248633
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.